Welltower
WELL
$239.22
+0.77%
Welltower Inc. is a real estate investment trust (REIT) that owns and operates a diversified healthcare portfolio, including senior housing, medical office buildings, and skilled nursing/post-acute care facilities. With over 2,800 properties across the U.S., Canada, and the U.K., Welltower is one of the largest healthcare REITs globally, distinguished by its scale and focus on demographics-driven demand. The current investor narrative centers on the company's robust recovery in senior housing fundamentals, driven by strong occupancy and rental rate growth, as well as its strategic expansion into international markets and capital recycling initiatives. Recent attention has also been drawn to the stock's outperformance relative to the broader REIT sector, fueled by expectations of continued earnings growth and potential benefits from a stabilizing interest rate environment.…
WELL
Welltower
$239.22
Related headlines
Investment Opinion: Should I buy WELL Today?
We rate Welltower a Buy, driven by its exceptional revenue growth and improving profitability. The consensus 'Buy' rating and average target of $255.50 support this view, implying 6.8% upside. Key evidence includes 38.4% YoY revenue growth, net margin expansion to 22%, and a strong balance sheet with a current ratio of 5.34. The forward PE of 74.1x is high but justified by expected earnings growth of 43.7%. Risks include valuation compression if growth slows or rates rise; we would downgrade to Hold if revenue growth falls below 20% or the payout ratio remains above 2.0x. Overall, the stock is overvalued relative to its history but fairly valued given its growth prospects.
Sign up to view all
WELL 12-Month Price Forecast
Welltower's strong operational performance and growth trajectory support a bullish stance. However, the elevated valuation and high payout ratio warrant caution. We would upgrade to high confidence if revenue growth remains above 30% and the payout ratio improves. Conversely, a downgrade to neutral would occur if growth decelerates or interest rates rise sharply.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Welltower's 12-month outlook, with a consensus price target around $256.73 and implied upside of +7.3% versus the current price.
Average Target
$256.73
0 analysts
Implied Upside
+7.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$215 - $292
Analyst target range
Welltower is covered by 22 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 1.73 (where 1 is Strong Buy and 5 is Sell). The average price target is $255.50, implying a 6.8% upside from the current price of $239.22. The distribution of ratings is not explicitly provided, but the 'Buy' consensus and recent upgrades from firms like JP Morgan (Neutral from Overweight) and Evercore ISI (Outperform) suggest a generally positive sentiment. The target price range spans from $192.00 (low) to $292.00 (high), indicating a wide dispersion of expectations. The high target of $292 assumes continued strong growth and potential multiple expansion, while the low target of $192 reflects concerns about a slowdown in senior housing fundamentals or broader market corrections. Recent institutional actions show a mix of upgrades and downgrades, with JP Morgan downgrading to Neutral in December 2025, but Evercore ISI upgrading to Outperform in November 2025, suggesting some divergence in views. Overall, the wide range indicates uncertainty about the sustainability of growth, but the consensus remains bullish.
Bulls vs Bears: WELL Investment Factors
Welltower presents a compelling growth story with exceptional revenue acceleration, expanding margins, and a solid balance sheet. The bull case is strong, supported by robust operational performance and analyst optimism. However, the elevated valuation and high payout ratio introduce significant risks. The key tension is whether the market's growth expectations are justified; if revenue growth decelerates or interest rates rise, the stock could face multiple compression. Currently, the bull case has stronger evidence given the fundamental momentum, but investors should monitor valuation and cash flow coverage closely.
Bullish
- Exceptional Revenue Growth: Q1 2026 revenue surged 38.4% YoY to $3.31B, accelerating from $2.39B in Q1 2025. This robust growth is driven by strong senior housing occupancy and rental rate increases, positioning Welltower as a top performer in the healthcare REIT sector.
- Expanding Profitability: Net margin improved to 22.0% in Q1 2026 from 10.8% a year earlier, with operating margin expanding to 16.9% from 15.8%. This operating leverage indicates efficient cost management and strong pricing power.
- Solid Balance Sheet and Liquidity: Debt-to-equity is a conservative 0.51, and the current ratio of 5.34 indicates ample liquidity. Free cash flow of $2.54B TTM comfortably covers the dividend, with a payout ratio of 2.0x, ensuring financial flexibility.
- Strong Analyst Consensus: With 22 analysts, the consensus is 'Buy' (mean score 1.73), and the average price target of $255.50 implies 6.8% upside. Recent upgrades from Evercore ISI (Outperform) underscore positive sentiment.
Bearish
- Elevated Valuation: Trailing PE of 131.6x and forward PE of 74.1x are at a significant premium to typical REIT multiples. The PS ratio of 11.6x is also high, suggesting the market is pricing in optimistic growth expectations.
- High Payout Ratio: The dividend payout ratio of 2.0x on trailing FCF indicates that dividends exceed free cash flow, which could pressure the dividend if cash flows decline. This is a red flag for income-focused investors.
- Interest Rate Sensitivity: As a REIT, Welltower is sensitive to interest rates. With a beta of 0.76, it is less volatile than the market, but rising rates could increase borrowing costs and compress valuation multiples.
- Potential Overextension: Trading near 52-week highs at $239.22, the stock may be overextended in the short term. The 1-month price change of -2.4% suggests some recent pullback, and a 12.6% max drawdown indicates vulnerability to corrections.
WELL Technical Analysis
Welltower's stock is in a clear long-term uptrend, with a 1-year price change of +43.3%, significantly outpacing the S&P 500's +20.5% over the same period. The current price of $239.22 sits at 93.7% of its 52-week range (between $163.75 low and $255.20 high), indicating the stock is trading near its highs, reflecting strong momentum and investor confidence. This positioning suggests the market is rewarding the company's operational performance, though it also raises the risk of short-term overextension.
Beta
0.76
0.76x market volatility
Max Drawdown
-12.6%
Largest decline past year
52-Week Range
$164-$255
Price range past year
Annual Return
+43.3%
Cumulative gain past year
| Period | WELL Return | S&P 500 |
|---|---|---|
| 1m | -2.4% | +3.6% |
| 3m | +10.7% | +2.7% |
| 6m | +14.9% | +11.4% |
| 1y | +43.3% | +18.7% |
| ytd | +28.0% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WELL Fundamental Analysis
Welltower's revenue trajectory is robust, with Q1 2026 revenue of $3.31 billion, representing a 38.4% year-over-year growth rate, a substantial acceleration from the prior year's quarterly figures (e.g., Q1 2025 revenue was $2.39 billion). The multi-quarter trend shows consistent sequential growth, from $2.39B in Q1 2025 to $3.31B in Q1 2026, driven by strong senior housing operating performance and contributions from recent acquisitions. This growth is broad-based, with the management service segment contributing $2.78 billion, indicating a diversified revenue stream. The company's profitability has improved markedly, with Q1 2026 net income of $728.7 million and a net margin of 22.0%, up from 10.8% in Q1 2025. Gross margin remained stable at 37.8%, while operating margin expanded to 16.9% from 15.8% a year earlier, reflecting operating leverage. Welltower's balance sheet is solid, with a debt-to-equity ratio of 0.51 and a current ratio of 5.34, indicating strong liquidity. Free cash flow for Q1 2026 was $281.7 million, and trailing twelve-month FCF was $2.54 billion, providing ample coverage for its dividend (payout ratio of 2.0 on a trailing basis). The company's ROE of 2.2% is modest, typical for REITs due to high asset base, but its interest coverage of 2.9x is adequate.
Quarterly Revenue
$3.3B
2026-03
Revenue YoY Growth
+38.4%
YoY Comparison
Gross Margin
37.8%
Latest Quarter
Free Cash Flow
$2.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WELL Overvalued?
Given that Welltower is profitable, the primary valuation metric is the price-to-earnings (PE) ratio. The trailing PE is 131.6x, while the forward PE is 74.1x, indicating the market expects significant earnings growth. The gap between trailing and forward PE suggests a 43.7% expected earnings increase over the next year, reflecting optimism about continued operational improvements. Compared to the industry average (not provided, but REITs typically trade at lower multiples), Welltower's PE is at a premium, likely justified by its superior growth and market position. Historically, Welltower's PE has ranged from around 43x to 343x over the past few years, with the current trailing PE of 131.6x near the higher end of that range, suggesting the market is pricing in optimistic expectations. The PS ratio of 11.6x is also elevated, but this is consistent with the company's high margins and growth trajectory.
PE
131.6x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 43x~172x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
60.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a high payout ratio of 2.0x, indicating dividends exceed free cash flow, which could be unsustainable if cash flows decline. The debt-to-equity ratio of 0.51 is manageable, but interest coverage of 2.9x is only adequate, leaving limited cushion if rates rise. Revenue concentration in senior housing exposes the company to occupancy and rate fluctuations, though diversification across medical office and international markets mitigates this somewhat. The net margin of 22% is strong, but the Q4 2025 operating loss of -$943.7M highlights potential volatility in earnings.
FAQ
Key risks include: 1) Valuation risk - the high PE could compress if growth slows; 2) Interest rate risk - rising rates increase borrowing costs and reduce REIT attractiveness; 3) Dividend risk - the payout ratio of 2.0x indicates dividends exceed FCF, risking a cut; 4) Operational risk - senior housing occupancy and rates could decline in an economic downturn. The most severe risk is a combination of slowing growth and rising rates, which could lead to a -20% or more correction.
Our 12-month forecast is bullish with a base case target of $240-$260, implying modest upside. The bull case targets $292 (30% probability) if growth accelerates, while the bear case targets $192 (20% probability) if growth disappoints. The base case (50% probability) assumes revenue growth moderates to 30% and the stock trades near the analyst average of $255.50. Overall, the most likely scenario is continued growth with some multiple compression.
Welltower is overvalued relative to its historical PE range (43x-343x) and the broader REIT sector, with a trailing PE of 131.6x. The forward PE of 74.1x implies the market expects 43.7% earnings growth, which is optimistic. The PS ratio of 11.6x is also elevated. This valuation suggests the market is pricing in continued strong growth, leaving little room for disappointment.
Welltower is a good buy for investors with a long-term horizon who can tolerate valuation risk. The stock offers a 6.8% upside to the average analyst target of $255.50, supported by strong revenue growth of 38.4% and improving margins. However, the high PE of 131.6x and payout ratio of 2.0x pose risks. It is a good buy if you believe in sustained senior housing growth and can withstand potential volatility.
Welltower is better suited for long-term investment given its growth trajectory and demographic tailwinds. The stock's beta of 0.76 indicates lower volatility than the market, but its high valuation makes it susceptible to short-term swings. A minimum holding period of 3-5 years is recommended to allow the growth story to play out and ride out any valuation corrections. Short-term traders may find opportunities, but the risk-reward is less favorable.